Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235755 · ClinicalTrials.gov registry record · Phase 3
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 539
- Enrollment target
NCT00235755 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 539 participants.
The verdict
NCT00235755, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 539 participants
- Enrollment target
Study Summary
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).
Interventions
- DRUG Placebo
- DRUG Retigabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 539 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235755
The ClinicalTrials.gov registry entry for NCT00235755 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00235755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235755 about?
NCT00235755 is a clinical study titled "Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy". This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).
What is the current status of trial NCT00235755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 539 participants. The study started on 2005-12. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00235755?
The interventions under investigation include: Placebo (DRUG), Retigabine (DRUG).
Who is sponsoring clinical trial NCT00235755?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.